Shares of Alpha Cognition Inc. (OTC:ACOGF – Get Free Report) fell 12.7% during trading on Wednesday . The company traded as low as C$0.36 and last traded at C$0.36. 159,766 shares changed hands during trading, an increase of 108% from the average session volume of 76,877 shares. The stock had previously closed at C$0.41.
Analyst Ratings Changes
Separately, Raymond James raised Alpha Cognition from a “hold” rating to a “moderate buy” rating in a research note on Monday, July 15th.
Read Our Latest Stock Analysis on ACOGF
Alpha Cognition Stock Down 12.7 %
Alpha Cognition (OTC:ACOGF – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported C($0.01) EPS for the quarter, beating analysts’ consensus estimates of C($0.04) by C$0.03. Sell-side analysts forecast that Alpha Cognition Inc. will post -0.19 earnings per share for the current fiscal year.
About Alpha Cognition
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
See Also
- Five stocks we like better than Alpha Cognition
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Should You Invest in Treasury Bills?
- Most Volatile Stocks, What Investors Need to Know
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.